Inhibikase Therapeutics, Inc.
IKT· Nasdaq
IKTInhibikase Therapeutics, Inc.
Filed Mar 31, 2023 · 10-K · 90 days after period end · 0000950170-23-011133
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|
| Revenue | $63.57K | $1.94K | $170.42K |
| Net Income | -$4.28M | -$5.04M | -$1.21M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibikase Therapeutics, Inc. · CIK 1750149 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end
